Aethlon Medical grants 21,815 RSUs to director
Shah Chetan reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Shah Chetan reported acquisition or exercise transactions in this Form 4 filing.
Aethlon Medical director Chetan Shah received a stock-based compensation grant. He was awarded 21,815 shares of Common Stock at a reference price of $2.29 per share, classified as a grant or award, increasing his directly held stake to 23,021 shares.
The award represents RSUs that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, conditioned on his continued service with the company on each vesting date. This is a routine compensation-related equity grant rather than an open-market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 21,815 | $2.29 | $50K |
Footnotes (1)
- F1. The Reporting Person was granted RSUs that vest in four equal quarterly installments on each of June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, subject to the Reporting Person's continued service with the Company on each such vesting date.
Key Figures
Key Terms
RSUs financial
vest financial
quarterly installments financial
continued service financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aethlon Medical (AEMD) disclose about director Chetan Shah?
When do Chetan Shah’s AEMD RSUs vest?
Is Chetan Shah’s AEMD Form 4 transaction an open-market buy or a grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.